Details of the Drug Combinations

General Information of This Drug (ID: DM7USVA)

Drug Name

Duvelisib DM7USVA

Synonyms

Duvelisib; 1201438-56-3; IPI-145; INK-1197; UNII-610V23S0JI; IPI 145; 610V23S0JI; INK-1147; Copiktra; IPI-145 (INK1197); Duvelisib [USAN:INN]; IPI145; INK1197; Copiktra (TN); AK145604; Duvelisib (IPI-145, INK1197); Duvel; Duvelisib

Indication

Disease Entry	ICD 11	Status	REF
Follicular lymphoma	2A80	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antiviral Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

7 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Duvelisib + Venetoclax	DCA4EJ0	Venetoclax	Chronic Lymphocytic Leukemia	[3]
Duvelisib + Azacitidine	DCAKUM1	Azacitidine	Non Hodgkin Lymphoma	[4]
Duvelisib + Romidepsin	DCSXV9B	Romidepsin	Lymphoma	[5]
Duvelisib + Bortezomib	DCUJJLM	Bortezomib	Lymphoma	[5]
Ruxolitinib + Duvelisib	DCTQ0GK	Ruxolitinib	T-cell Lymphomas	[6]
Duvelisib + Docetaxel	DCA97LH	Docetaxel	Squamous Cell Carcinoma of the Head and Neck (SCCHN)	[7]
Duvelisib + Ibrutinib	DCL16B4	Ibrutinib	Small Lymphocytic Leukemia (SLL)	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 211155
2	ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT02640833) A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
4	ClinicalTrials.gov (NCT05065866) Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
5	ClinicalTrials.gov (NCT02783625) Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
6	ClinicalTrials.gov (NCT05010005) A Study of Ruxolitinib and Duvelisib in People With Lymphoma
7	ClinicalTrials.gov (NCT05057247) Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
8	ClinicalTrials.gov (NCT04209621) Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma